Stockreport

ProMIS Neurosciences Showcases Preclinical Data on Platform Derived Vaccines for Neurodegenerative Diseases at the American Academy of Neurology 2025 Annual Meeting

ProMIS Neurosciences Inc. - Common Shares  (PMN) 
PDF CAMBRIDGE, Massachusetts , March 13, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation [Read more]